The global immune checkpoint inhibitors market size accounted for USD 58.53 billion in 2025 and is predicted to surpass around USD 229.60 billion by 2034, representing a healthy CAGR of 16.40% between 2025 and 2034. The North America immune checkpoint inhibitors market size was calculated at USD 23.63 billion in 2024 and is expected to grow at a fastest CAGR of 16.42% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Immune Checkpoint Inhibitors Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Immune Checkpoint Inhibitors Market, by Drug Type
8.1.1 CTLA-4 Inhibitor
8.1.1.1. Market Revenue and Forecast
8.1.2. PD-1 Inhibitor
8.1.2.1. Market Revenue and Forecast
8.1.3. PD-L1 Inhibitor
8.1.3.1. Market Revenue and Forecast
9.1. Immune Checkpoint Inhibitors Market, by Disease Indication
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast
9.1.2. Bladder Cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Melanoma
9.1.3.1. Market Revenue and Forecast
9.1.4. Hodgkin lymphoma
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Immune Checkpoint Inhibitors Market, by End-Users
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Academic & Research Institutions
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type
11.1.2. Market Revenue and Forecast, by Disease Indication
11.1.3. Market Revenue and Forecast, by End-Users
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type
11.1.4.2. Market Revenue and Forecast, by Disease Indication
11.1.4.3. Market Revenue and Forecast, by End-Users
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type
11.1.5.2. Market Revenue and Forecast, by Disease Indication
11.1.5.3. Market Revenue and Forecast, by End-Users
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type
11.2.2. Market Revenue and Forecast, by Disease Indication
11.2.3. Market Revenue and Forecast, by End-Users
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type
11.2.4.2. Market Revenue and Forecast, by Disease Indication
11.2.4.3. Market Revenue and Forecast, by End-Users
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type
11.2.5.2. Market Revenue and Forecast, by Disease Indication
11.2.5.3. Market Revenue and Forecast, by End-Users
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type
11.2.6.2. Market Revenue and Forecast, by Disease Indication
11.2.6.3. Market Revenue and Forecast, by End-Users
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type
11.2.7.2. Market Revenue and Forecast, by Disease Indication
11.2.7.3. Market Revenue and Forecast, by End-Users
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type
11.3.2. Market Revenue and Forecast, by Disease Indication
11.3.3. Market Revenue and Forecast, by End-Users
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type
11.3.4.2. Market Revenue and Forecast, by Disease Indication
11.3.4.3. Market Revenue and Forecast, by End-Users
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type
11.3.5.2. Market Revenue and Forecast, by Disease Indication
11.3.5.3. Market Revenue and Forecast, by End-Users
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type
11.3.6.2. Market Revenue and Forecast, by Disease Indication
11.3.6.3. Market Revenue and Forecast, by End-Users
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type
11.3.7.2. Market Revenue and Forecast, by Disease Indication
11.3.7.3. Market Revenue and Forecast, by End-Users
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type
11.4.2. Market Revenue and Forecast, by Disease Indication
11.4.3. Market Revenue and Forecast, by End-Users
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type
11.4.4.2. Market Revenue and Forecast, by Disease Indication
11.4.4.3. Market Revenue and Forecast, by End-Users
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type
11.4.5.2. Market Revenue and Forecast, by Disease Indication
11.4.5.3. Market Revenue and Forecast, by End-Users
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type
11.4.6.2. Market Revenue and Forecast, by Disease Indication
11.4.6.3. Market Revenue and Forecast, by End-Users
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type
11.4.7.2. Market Revenue and Forecast, by Disease Indication
11.4.7.3. Market Revenue and Forecast, by End-Users
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type
11.5.2. Market Revenue and Forecast, by Disease Indication
11.5.3. Market Revenue and Forecast, by End-Users
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type
11.5.4.2. Market Revenue and Forecast, by Disease Indication
11.5.4.3. Market Revenue and Forecast, by End-Users
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type
11.5.5.2. Market Revenue and Forecast, by Disease Indication
11.5.5.3. Market Revenue and Forecast, by End-Users
12.1. AstraZeneca PLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company (ARMO Biosciences.)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline PLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Roche Holding AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Incyte Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi, Merck & Co., Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA (EMD Serono Inc.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample